PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Medical Device Technology

Background:

• Transcatheter aortic valve implantation (TAVI) is a key treatment for severe symptomatic aortic stenosis in high-risk or inoperable patients.
• Surgical outcomes and device technology for TAVI have significantly improved, leading to its consideration in lower-risk patient groups.

Purpose of the Study:

• To evaluate the efficacy and safety of TAVI in patients with severe symptomatic aortic stenosis who are not candidates for surgery or have high surgical risk.
• To address the lack of robust clinical trial evidence supporting the expansion of TAVI to lower-risk patient populations.

Main Methods:

• The PARTNER 2A trial investigated TAVI versus surgical aortic valve replacement in intermediate-risk patients.
• The SAPIEN 3 trial focused on the outcomes of TAVI using an advanced device in a broad patient population.

Main Results:

• Both trials demonstrated favorable outcomes with TAVI, challenging the traditional indications.
• The studies provide crucial data on the effectiveness and safety of TAVI in a wider range of patients.

Conclusions:

• TAVI is a viable and effective option for severe symptomatic aortic stenosis, even in patients with lower surgical risk.
• Further research and evidence from trials like PARTNER 2A and SAPIEN 3 are essential for refining TAVI indications and improving patient selection.